Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. uri icon

Overview

publication date

  • April 18, 2019

Research

keywords

  • Drug Resistance, Neoplasm
  • Janus Kinase 3
  • Leukemia, Prolymphocytic, T-Cell
  • Mutation
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Pyrroles

Identity

PubMed Central ID

  • PMC8162842

Scopus Document Identifier

  • 85064615213

Digital Object Identifier (DOI)

  • 10.1200/PO.17.00019

PubMed ID

  • 30997845

Additional Document Info

volume

  • 60

issue

  • 7